PL3159409T3 - Antysensowne kwasy nukleinowe do zastosowania do leczenia dystrofii mięśniowej duchenne'a - Google Patents

Antysensowne kwasy nukleinowe do zastosowania do leczenia dystrofii mięśniowej duchenne'a

Info

Publication number
PL3159409T3
PL3159409T3 PL15810097T PL15810097T PL3159409T3 PL 3159409 T3 PL3159409 T3 PL 3159409T3 PL 15810097 T PL15810097 T PL 15810097T PL 15810097 T PL15810097 T PL 15810097T PL 3159409 T3 PL3159409 T3 PL 3159409T3
Authority
PL
Poland
Prior art keywords
duchenne
treatment
nucleic acid
antisense nucleic
muscular dystrophy
Prior art date
Application number
PL15810097T
Other languages
English (en)
Inventor
Naoki Watanabe
Yuuichirou Tone
Shin'ichi Takeda
Tetsuya Nagata
Original Assignee
Nippon Shinyaku Co., Ltd.
National Center Of Neurology And Psychiatry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co., Ltd., National Center Of Neurology And Psychiatry filed Critical Nippon Shinyaku Co., Ltd.
Publication of PL3159409T3 publication Critical patent/PL3159409T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PL15810097T 2014-06-17 2015-06-16 Antysensowne kwasy nukleinowe do zastosowania do leczenia dystrofii mięśniowej duchenne'a PL3159409T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014124157 2014-06-17
EP15810097.4A EP3159409B1 (en) 2014-06-17 2015-06-16 Antisense nucleic acid for use in the treatment of duchenne's muscular dystrophy
PCT/JP2015/067238 WO2015194520A1 (ja) 2014-06-17 2015-06-16 アンチセンス核酸

Publications (1)

Publication Number Publication Date
PL3159409T3 true PL3159409T3 (pl) 2020-05-18

Family

ID=54935505

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15810097T PL3159409T3 (pl) 2014-06-17 2015-06-16 Antysensowne kwasy nukleinowe do zastosowania do leczenia dystrofii mięśniowej duchenne'a
PL19208809.4T PL3660154T3 (pl) 2014-06-17 2015-06-16 Antysensowne kwasy nukleinowe do zastosowania do leczenia dystrofii mięśniowej duchenne'a

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL19208809.4T PL3660154T3 (pl) 2014-06-17 2015-06-16 Antysensowne kwasy nukleinowe do zastosowania do leczenia dystrofii mięśniowej duchenne'a

Country Status (30)

Country Link
US (4) US9840706B2 (pl)
EP (3) EP3159409B1 (pl)
JP (6) JP6208349B2 (pl)
KR (1) KR102335810B1 (pl)
CN (2) CN106661577B (pl)
AU (3) AU2015277924B2 (pl)
BR (2) BR122020020864B1 (pl)
CA (1) CA2951221A1 (pl)
CO (1) CO2017000357A2 (pl)
CY (1) CY1122462T1 (pl)
DK (1) DK3159409T3 (pl)
ES (2) ES3027057T3 (pl)
HR (1) HRP20200042T1 (pl)
HU (1) HUE047502T2 (pl)
IL (1) IL249574B (pl)
LT (1) LT3159409T (pl)
MX (2) MX373052B (pl)
MY (2) MY194170A (pl)
PH (1) PH12016502501A1 (pl)
PL (2) PL3159409T3 (pl)
PT (1) PT3159409T (pl)
RS (1) RS59764B1 (pl)
RU (1) RU2695430C2 (pl)
SG (2) SG11201610130VA (pl)
SI (1) SI3159409T1 (pl)
SM (1) SMT202000006T1 (pl)
TW (2) TWI666317B (pl)
UA (1) UA121117C2 (pl)
WO (1) WO2015194520A1 (pl)
ZA (1) ZA201700142B (pl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2695430C2 (ru) * 2014-06-17 2019-07-23 Ниппон Синяку Ко., Лтд. Антисмысловые нуклеиновые кислоты
SI3351633T1 (sl) 2015-09-15 2020-09-30 Nippon Shinyaku Co., Ltd. Protismiselna nukleinska kislina
JP6875684B2 (ja) * 2015-09-16 2021-05-26 日本新薬株式会社 筋萎縮症治療用アンチセンス核酸
JP7511326B2 (ja) 2015-10-09 2024-07-05 ウェイブ ライフ サイエンシズ リミテッド オリゴヌクレオチド組成物およびその方法
JP2019513371A (ja) 2016-04-01 2019-05-30 アビディティー バイオサイエンシーズ エルエルシー 核酸ポリペプチド組成物とその使用
TW201811807A (zh) 2016-06-30 2018-04-01 美商薩羅塔治療公司 用於肌肉萎縮症之外顯子跳躍寡聚物
SMT202200366T1 (it) 2016-12-19 2022-11-18 Sarepta Therapeutics Inc Coniugati di oligomeri per salto di esone per distrofia muscolare
SI3554554T1 (sl) 2016-12-19 2023-02-28 Sarepta Therapeutics, Inc. Oligomerni konjugati, ki preskakujejo ekson za mišično distrofijo
IL297528A (en) 2016-12-19 2022-12-01 Sarepta Therapeutics Inc Exon-skipping oligomer conjugates for muscular dystrophy
MX2019008199A (es) 2017-01-06 2019-11-25 Avidity Biosciences Llc Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
US20200282074A1 (en) * 2017-09-22 2020-09-10 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and methods of inducing exon skipping
JP7506601B2 (ja) 2017-12-06 2024-06-26 アビディティー バイオサイエンシーズ，インク． 筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法
US10758629B2 (en) 2018-05-29 2020-09-01 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
EP3829595A4 (en) 2018-08-02 2022-08-24 Dyne Therapeutics, Inc. MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
IL282818B1 (en) * 2018-11-02 2026-04-01 Biomarin Tech Bv Bispecific antisense oligonucleotides for dystrophin exon skipping
US12497615B2 (en) 2019-04-25 2025-12-16 Avidity Biosciences, Inc. Nucleic acid compositions and methods of multi-exon skipping
EP4007633A4 (en) * 2019-08-02 2024-05-08 Research Institute at Nationwide Children's Hospital NUCLEIC ACIDS TARGETING EXON 44 AND RECOMBINANT ADENO-ASSOCIATED VIRUS COMPRISING SAID NUCLEIC ACIDS FOR THE TREATMENT OF DYSTROPHIN-BASED MYOPATHIES
US20230140736A1 (en) * 2020-02-28 2023-05-04 Nippon Shinyaku Co., Ltd. Antisense nucleic acid inducing skipping of exon 51
US11555190B2 (en) 2020-03-19 2023-01-17 Avidity Biosciences, Inc. Compositions and methods of treating Facioscapulohumeral muscular dystrophy
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
IL296394A (en) 2020-03-20 2022-11-01 Keros Therapeutics Inc Type ii activin receptor chimeras and methods of using them
MX2023012559A (es) 2021-04-30 2023-12-15 Sarepta Therapeutics Inc Métodos de tratamiento para la distrofia muscular.
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
IL309936A (en) 2021-07-09 2024-03-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of dystrophinopathy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US20240390508A1 (en) 2021-08-21 2024-11-28 Takeda Pharmaceutical Company Limited Human transferrin receptor binding peptide-drug conjugate
US20240366775A1 (en) 2021-08-24 2024-11-07 Peptidream Inc. Human transferrin receptor binding antibody-peptide conjugate
MX2024003266A (es) 2021-09-16 2024-04-03 Avidity Biosciences Inc Composiciones y metodos de tratamiento de la distrofia muscular facioescapulohumeral.
CA3244382A1 (en) 2021-12-27 2025-02-26 Nippon Shinyaku Co., Ltd. PROCESS FOR THE PRODUCTION OF OLIGONUCLEIC ACID COMPOUNDS
EP4215614A1 (en) 2022-01-24 2023-07-26 Dynacure Combination therapy for dystrophin-related diseases
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies
WO2023168427A1 (en) 2022-03-03 2023-09-07 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping
JP2025509438A (ja) 2022-03-17 2025-04-11 サレプタ セラピューティクス， インコーポレイテッド ホスホロジアミデートモルホリノオリゴマーコンジュゲート
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
WO2025174995A1 (en) * 2024-02-13 2025-08-21 Keros Therapeutics, Inc. Methods of using activin a and myostatin signaling inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3398378B2 (ja) 1989-12-20 2003-04-21 アンチビラルス・インコーポレイテツド リン含有キラルインターサブユニットリンケージを有する非電荷モルホリノ―基体ポリマー
JP2924179B2 (ja) 1993-02-19 1999-07-26 日本新薬株式会社 グリセロール誘導体，デバイス及び医薬組成物
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
JP4777777B2 (ja) 2002-11-25 2011-09-21 雅文 松尾 ｍＲＮＡ前駆体のスプライシングを修飾するＥＮＡ核酸医薬
CA2524255C (en) 2003-03-21 2014-02-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
ATE498685T1 (de) * 2004-06-28 2011-03-15 Univ Western Australia Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
EP1857548A1 (en) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
JP5143450B2 (ja) * 2007-03-14 2013-02-13 斉 大戸 Ｈｌａ−ｂローカスにおける新規アリル
AU2008317566B2 (en) * 2007-10-26 2014-05-01 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
MX2010004955A (es) 2007-11-15 2010-06-30 Avi Biopharma Inc Metodo de sintesis de oligomeros de morfolina.
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
CN112574988A (zh) * 2008-10-24 2021-03-30 萨雷普塔治疗公司 用于dmd的多外显子跳跃组合物
CA2759899A1 (en) 2009-04-24 2010-10-28 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
LT2499249T (lt) 2009-11-12 2018-12-27 The University Of Western Australia Priešprasmės molekulės ir patologijų gydymo būdai
TWI541024B (zh) * 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
EP2672977A1 (en) 2011-02-08 2013-12-18 The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System Antisense oligonucleotides
CN117721110A (zh) 2011-12-28 2024-03-19 日本新药株式会社 反义核酸
CN112251436A (zh) 2012-01-27 2021-01-22 比奥马林技术公司 治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
EP2870246B1 (en) * 2012-07-03 2019-09-11 BioMarin Technologies B.V. Oligonucleotide for the treatment of muscular dystrophy patients
JP2014124157A (ja) 2012-12-27 2014-07-07 Nihon Cornstarch Corp コーヒー飲料
SMT201900169T1 (it) 2014-03-12 2019-05-10 Nippon Shinyaku Co Ltd Acido nucleico antisenso
RU2695430C2 (ru) * 2014-06-17 2019-07-23 Ниппон Синяку Ко., Лтд. Антисмысловые нуклеиновые кислоты

Also Published As

Publication number Publication date
JP6208349B2 (ja) 2017-10-04
ES2765463T3 (es) 2020-06-09
US20170204410A1 (en) 2017-07-20
AU2015277924A1 (en) 2017-02-02
PL3660154T3 (pl) 2025-07-28
IL249574A0 (en) 2017-02-28
NZ728103A (en) 2021-11-26
EP4596047A2 (en) 2025-08-06
BR112016029369B1 (pt) 2020-12-08
CO2017000357A2 (es) 2017-06-09
SG10201912858VA (en) 2020-02-27
PH12016502501A1 (en) 2017-03-22
KR20170017939A (ko) 2017-02-15
NZ765451A (en) 2024-04-26
JP2024023899A (ja) 2024-02-21
WO2015194520A1 (ja) 2015-12-23
DK3159409T3 (da) 2020-01-27
RU2017101172A3 (pl) 2018-12-24
RU2017101172A (ru) 2018-07-17
CN106661577B (zh) 2020-05-12
IL249574B (en) 2021-02-28
KR102335810B1 (ko) 2021-12-03
UA121117C2 (uk) 2020-04-10
JP7041879B2 (ja) 2022-03-25
TWI721461B (zh) 2021-03-11
MX2016016526A (es) 2017-04-04
JPWO2015194520A1 (ja) 2017-04-20
MX2020004417A (es) 2020-08-06
JP6701139B2 (ja) 2020-05-27
TW201936922A (zh) 2019-09-16
US20250084412A1 (en) 2025-03-13
AU2021203383B2 (en) 2023-11-30
PT3159409T (pt) 2020-01-21
JP2020182459A (ja) 2020-11-12
JP2018027087A (ja) 2018-02-22
SI3159409T1 (sl) 2020-02-28
RU2019121781A (ru) 2019-07-22
US11193125B2 (en) 2021-12-07
AU2021203383A1 (en) 2021-06-24
MY194170A (en) 2022-11-16
AU2024201290A1 (en) 2024-03-21
SG11201610130VA (en) 2017-01-27
CY1122462T1 (el) 2021-01-27
RS59764B1 (sr) 2020-02-28
CN106661577A (zh) 2017-05-10
JP2022082539A (ja) 2022-06-02
EP3159409A4 (en) 2018-01-10
ZA201700142B (en) 2020-05-27
EP3159409B1 (en) 2019-12-04
LT3159409T (lt) 2020-01-27
US12060556B2 (en) 2024-08-13
BR112016029369A2 (pt) 2018-01-09
EP3159409A1 (en) 2017-04-26
EP3660154C0 (en) 2025-04-16
CA2951221A1 (en) 2015-12-23
HUE047502T2 (hu) 2020-04-28
CN111575282B (zh) 2024-05-14
SMT202000006T1 (it) 2020-03-13
HRP20200042T1 (hr) 2020-03-20
BR122020020864B1 (pt) 2022-06-21
US20180044675A1 (en) 2018-02-15
EP3660154A1 (en) 2020-06-03
AU2015277924B2 (en) 2021-02-25
JP2026010142A (ja) 2026-01-21
TW201625274A (zh) 2016-07-16
US20220049257A1 (en) 2022-02-17
EP4596047A3 (en) 2025-10-22
ES3027057T3 (en) 2025-06-12
US9840706B2 (en) 2017-12-12
MX373052B (es) 2020-05-11
MX420315B (es) 2025-02-10
CN111575282A (zh) 2020-08-25
MY202674A (en) 2024-05-14
RU2695430C2 (ru) 2019-07-23
TWI666317B (zh) 2019-07-21
EP3660154B1 (en) 2025-04-16

Similar Documents

Publication Publication Date Title
HUE047502T2 (hu) Antiszensz nukleinsav Duchenne izomsorvadás kezelésében történõ alkalmazásra
IL290160A (en) Preparations and methods for the treatment of Duchenne muscular dystrophy and related disorders
IL284423A (en) Antisense oligonucleotides for the treatment of Pompe disease
PL3334422T3 (pl) Zastosowanie kwasu kannabidiolowego w leczeniu padaczki
IL247663B (en) Antisense oligomers for skipping exon 51 in the human dystrophin gene
IL251390A0 (en) Polysaccharide and nucleic acid formulations that include viscosity-reducing agents
HUE048551T2 (hu) Nukleinsav-szerkezetek és génterápiás vektorok Wilson-kór és egyéb állapotok kezelésében történõ alkalmazásra
AU2022271491B2 (en) Antisense oligonucleotides for use in treating alzheimer's disease
IL247349A0 (en) Anionic polyplexes for use in nucleic acid transduction
PT3286317T (pt) Inibidor de dinamina 2 para o tratamento de distrofia muscular de duchenne
LT3307277T (lt) Viengrandžiai oligonukleotidai, skirti naudoti mediciniškai gydant odos sutrikimus
IL274203A (en) A pharmaceutical solution containing dopamine for use in the treatment of Parkinson's disease
GB201513543D0 (en) Compositions for use in the treatment of diabetes
IL262013A (en) Composition for the treatment of duchenne muscular dystrophy
GB201612920D0 (en) Composition for the treatment of Duchenne Muscular Dystrophy
GB201605380D0 (en) Composition for the treatment of duchenne muscular dystrophy
GB201605383D0 (en) Composition for the treatment of duchenne muscular dystrophy
IL249871A0 (en) 2-(2-Methylamino-pyrimidin-4-yl)-h1-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amine for use In the treatment of pain due to osteoarthritis
GB201518052D0 (en) Parkinson's disease treatment
GB201412638D0 (en) Artist's implement